Symbols / AKTX $0.22 +4.35%
AKTX Chart
About
Akari Therapeutics, Plc, an oncology company, develops next-generation antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, colon, and prostate. Its payloads include PH5, which inhibits DNA mismatch repair (MMR) and DNA damage response (DDR) to generate neoepitopes, and PH6, which inhibits DNA transcription in cancer cells and co-opted immune cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Boston, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 9.89M |
| Enterprise Value | 14.80B | Income | -15.77M | Sales | — |
| Book/sh | 0.70 | Cash/sh | 2484000.00 | Dividend Yield | — |
| Payout | 0.00% | Employees | 8 | IPO | — |
| P/E | inf | Forward P/E | -0.72 | PEG | — |
| P/S | — | P/B | 0.31 | P/C | — |
| EV/EBITDA | -1125.04 | EV/Sales | — | Quick Ratio | 0.16 |
| Current Ratio | 0.19 | Debt/Eq | 9.77 | LT Debt/Eq | — |
| EPS (ttm) | 0.00 | EPS next Y | -0.30 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-11-13 17:00 | ROA | -34.20% |
| ROE | -197.24% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 45.78M |
| Shs Float | 43.05B | Short Float | 0.62% | Short Ratio | 0.85 |
| Short Interest | — | 52W High | 1.73 | 52W Low | 0.20 |
| Beta | 0.34 | Avg Volume | 666.82K | Volume | 826.87K |
| Target Price | $3.00 | Recom | Strong_buy | Prev Close | $0.21 |
| Price | $0.22 | Change | 4.35% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$3.00
Mean price target
2. Current target
$0.22
Latest analyst target
3. DCF / Fair value
$0.11
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.22
Low
$1.00
High
$7.00
Mean
$3.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-01-05 | init | Ladenburg Thalmann | — → Buy | $1 |
| 2025-09-09 | reit | HC Wainwright & Co. | Buy → Buy | $2 |
| 2025-07-18 | init | Maxim Group | — → Buy | $5 |
- Akari Therapeutics (AKTX) Alters ADS to Ordinary Shares Ratio - GuruFocus ue, 17 Mar 2026 21
- Cancer biotech Akari charts new ADC toward first human trial - Stock Titan Fri, 13 Mar 2026 13
- Akari Therapeutics Announces ADS Ratio Change - Yahoo Finance Singapore ue, 17 Mar 2026 20
- 12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga ue, 17 Mar 2026 21
- Akari Therapeutics Highlights Strategic Progress and Pipeline Expansion Under CEO Abizer Gaslightwala - Quiver Quantitative Fri, 13 Mar 2026 13
- Director Neal James acquires Akari (AKTX) ADS warrants via placement and note swap - Stock Titan Mon, 16 Mar 2026 21
- Insiders Re-Evaluate Their US$1.81m Stock Purchase As Akari Therapeutics Falls To US$19m - simplywall.st Fri, 14 Nov 2025 08
- Akari Therapeutics Releases CEO Corner Highlighting Strategic Progress and Path to Clinical Development Under CEO Abizer Gaslightwala - Bitget Fri, 13 Mar 2026 13
- 12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga Mon, 16 Mar 2026 21
- Akari Therapeutics Announces Promising Preclinical Data for AKTX-101 Targeting K-Ras G12V Mutated Pancreatic Cancer - Quiver Quantitative ue, 09 Dec 2025 08
- Dana-Farber cancer leader joins Akari’s RNA-splicing drug effort - Stock Titan hu, 26 Feb 2026 08
- Akari Therapeutics (AKTX) filing: Hoyoung Huh reports 18.4% ownership - Stock Titan Wed, 04 Mar 2026 21
- Akari Therapeutics Publishes CEO Corner Segment Highlighting Progress and Future Opportunities - Quiver Quantitative hu, 04 Dec 2025 08
- Akari Therapeutics (NASDAQ: AKTX) holder reports 8.9% ownership - Stock Titan Wed, 04 Mar 2026 21
- Akari Therapeutics Announces $5 Million Financing Through ADS Offering and Warrants - Quiver Quantitative ue, 16 Dec 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 58619 | 43964 | — | Stock Award(Grant) at price 0.75 per share. | FARAG KAMEEL D | Chief Financial Officer | — | 2025-10-31 00:00:00 | D |
| 1 | 6277 | 4645 | — | Stock Award(Grant) at price 0.74 per share. | FARAG KAMEEL D | Chief Financial Officer | — | 2025-10-22 00:00:00 | D |
| 2 | 21000 | 19540 | — | Purchase at price 0.90 - 0.94 per share. | GASLIGHTWALA ABIZER | Chief Executive Officer | — | 2025-08-25 00:00:00 | D |
| 3 | 6146 | 7120 | — | Purchase at price 1.15 - 1.16 per share. | GASLIGHTWALA ABIZER | Chief Executive Officer | — | 2025-06-24 00:00:00 | D |
| 4 | 10000 | 12000 | — | Purchase at price 1.20 per share. | GASLIGHTWALA ABIZER | Chief Executive Officer | — | 2025-06-20 00:00:00 | D |
| 5 | 15000 | 18000 | — | Purchase at price 1.20 per share. | GASLIGHTWALA ABIZER | Chief Executive Officer | — | 2025-06-17 00:00:00 | D |
| 6 | 45000 | 54350 | — | Stock Award(Grant) at price 1.19 - 1.23 per share. | GASLIGHTWALA ABIZER | Chief Executive Officer | — | 2025-06-13 00:00:00 | D |
| 7 | 20000 | 25400 | — | Stock Award(Grant) at price 1.27 per share. | GASLIGHTWALA ABIZER | Chief Executive Officer | — | 2025-06-10 00:00:00 | D |
| 8 | 4464 | 4046 | — | Stock Award(Grant) at price 0.91 per share. | NEAL JAMES R | Director | — | 2025-03-06 00:00:00 | D |
| 9 | 892857 | 809286 | — | Stock Award(Grant) at price 0.91 per share. | HUH HOYOUNG | Director and Beneficial Owner of more than 10% of a Class of Security | — | 2025-03-06 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -16.63M | -16.74M | -28.52M | -17.02M |
| TotalUnusualItems | -2.90M | 6.74M | 5.44M | -193.22K |
| TotalUnusualItemsExcludingGoodwill | -2.90M | 6.74M | 5.44M | -193.22K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -19.79M | -10.01M | -17.75M | -17.42M |
| ReconciledDepreciation | 14.00K | 4.00K | 4.00K | 4.13K |
| EBITDA | -19.53M | -10.00M | -23.08M | -17.21M |
| EBIT | -19.55M | -10.01M | -23.09M | -17.21M |
| NetInterestIncome | -236.00K | 82.00K | 46.00K | 10.60K |
| InterestExpense | 244.00K | 0.00 | ||
| InterestIncome | 8.00K | 82.00K | 46.00K | 10.60K |
| NormalizedIncome | -16.89M | -16.74M | -23.18M | -17.23M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -19.79M | -10.01M | -17.75M | -17.42M |
| TotalExpenses | 16.65M | 16.81M | 23.09M | 17.21M |
| TotalOperatingIncomeAsReported | -21.64M | -16.81M | -23.09M | -17.21M |
| DilutedAverageShares | 11.94M | 4.89M | 3.12M | 2.15M |
| BasicAverageShares | 11.94M | 4.89M | 3.12M | 2.15M |
| DilutedEPS | 0.00 | 0.00 | -5.40 | -8.12 |
| BasicEPS | 0.00 | 0.00 | -5.40 | -8.12 |
| DilutedNIAvailtoComStockholders | -19.79M | -10.01M | -17.75M | -17.42M |
| NetIncomeCommonStockholders | -19.79M | -10.01M | -17.75M | -17.42M |
| NetIncome | -19.79M | -10.01M | -17.75M | -17.42M |
| NetIncomeIncludingNoncontrollingInterests | -19.79M | -10.01M | -17.75M | -17.42M |
| NetIncomeContinuousOperations | -19.79M | -10.01M | -17.75M | -17.42M |
| PretaxIncome | -19.79M | -10.01M | -17.75M | -17.42M |
| OtherIncomeExpense | -2.91M | 6.72M | 5.29M | -220.70K |
| OtherNonOperatingIncomeExpenses | -3.00K | -19.00K | -142.00K | -27.48K |
| SpecialIncomeCharges | -5.00M | 0.00 | ||
| RestructuringAndMergernAcquisition | 5.00M | 0.00 | ||
| GainOnSaleOfSecurity | 2.09M | 6.74M | 5.44M | -193.22K |
| NetNonOperatingInterestIncomeExpense | -236.00K | 82.00K | 46.00K | 10.60K |
| InterestExpenseNonOperating | 244.00K | 0.00 | ||
| InterestIncomeNonOperating | 8.00K | 82.00K | 46.00K | 10.60K |
| OperatingIncome | -16.65M | -16.81M | -23.09M | -17.21M |
| OperatingExpense | 16.65M | 16.81M | 23.09M | 17.21M |
| ResearchAndDevelopment | 6.98M | 5.45M | 9.56M | 9.13M |
| SellingGeneralAndAdministration | 9.66M | 11.36M | 13.53M | 8.08M |
| GeneralAndAdministrativeExpense | 9.66M | 11.36M | 13.53M | 8.08M |
| OtherGandA | 9.66M | 11.36M | 13.53M | 8.08M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 53.19B | 13.23B | 7.44B | 4.76B |
| ShareIssued | 53.19B | 13.23B | 7.44B | 4.76B |
| NetDebt | 661.00K | |||
| TotalDebt | 3.26M | |||
| TangibleBookValue | -25.38M | -243.00K | 1.77M | 5.53M |
| InvestedCapital | 25.49M | -229.00K | 1.79M | 5.55M |
| WorkingCapital | -16.96M | -243.00K | 1.77M | 5.53M |
| NetTangibleAssets | -25.38M | -243.00K | 1.77M | 5.53M |
| CommonStockEquity | 22.23M | -229.00K | 1.79M | 5.55M |
| TotalCapitalization | 22.23M | -229.00K | 1.79M | 5.55M |
| TotalEquityGrossMinorityInterest | 22.23M | -229.00K | 1.79M | 5.55M |
| StockholdersEquity | 22.23M | -229.00K | 1.79M | 5.55M |
| GainsLossesNotAffectingRetainedEarnings | -738.00K | -1.04M | -771.00K | -540.97K |
| OtherEquityAdjustments | -738.00K | -1.04M | -771.00K | -540.97K |
| RetainedEarnings | -247.25M | -227.46M | -217.45M | -199.71M |
| AdditionalPaidInCapital | 264.90M | 226.95M | 219.27M | 205.32M |
| CapitalStock | 5.32M | 1.32M | 745.00K | 475.97K |
| CommonStock | 5.32M | 1.32M | 745.00K | 475.97K |
| TotalLiabilitiesNetMinorityInterest | 28.33M | 4.58M | 12.04M | 6.09M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 8.42M | 0.00 | 0.00 | 0.00 |
| OtherNonCurrentLiabilities | 383.00K | |||
| NonCurrentDeferredLiabilities | 8.04M | 0.00 | ||
| NonCurrentDeferredTaxesLiabilities | 8.04M | 0.00 | ||
| CurrentLiabilities | 19.91M | 4.58M | 12.04M | 6.09M |
| OtherCurrentLiabilities | 1.11M | 1.35M | 7.95M | 1.12M |
| CurrentDebtAndCapitalLeaseObligation | 3.26M | |||
| CurrentDebt | 3.26M | |||
| OtherCurrentBorrowings | 950.00K | |||
| CurrentNotesPayable | 2.31M | 0.00 | ||
| PensionandOtherPostRetirementBenefitPlansCurrent | 473.00K | 187.00K | 1.43M | |
| PayablesAndAccruedExpenses | 15.07M | 3.05M | 2.67M | 4.97M |
| CurrentAccruedExpenses | 2.66M | 1.38M | 1.72M | 3.18M |
| Payables | 12.41M | 1.67M | 947.00K | 1.79M |
| AccountsPayable | 12.41M | 1.67M | 947.00K | 1.79M |
| TotalAssets | 50.56M | 4.36M | 13.83M | 11.65M |
| TotalNonCurrentAssets | 47.61M | 14.00K | 17.00K | 22.93K |
| GoodwillAndOtherIntangibleAssets | 47.61M | 14.00K | 17.00K | 22.93K |
| OtherIntangibleAssets | 39.18M | 14.00K | 17.00K | 22.93K |
| Goodwill | 8.43M | |||
| NetPPE | 0.00 | |||
| AccumulatedDepreciation | -164.94K | |||
| GrossPPE | 164.94K | |||
| MachineryFurnitureEquipment | 164.94K | |||
| CurrentAssets | 2.95M | 4.34M | 13.81M | 11.63M |
| OtherCurrentAssets | 201.00K | 197.00K | 100.00K | 90.30K |
| RestrictedCash | 60.00K | 0.00 | ||
| PrepaidAssets | 92.00K | 299.00K | 465.00K | 2.17M |
| CashCashEquivalentsAndShortTermInvestments | 2.60M | 3.85M | 13.25M | 9.36M |
| CashAndCashEquivalents | 2.60M | 3.85M | 13.25M | 9.36M |
| CashFinancial | 2.60M | 3.85M | 13.25M | 9.36M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -12.55M | -16.43M | -21.50M | -18.85M |
| RepaymentOfDebt | -1.85M | 0.00 | ||
| IssuanceOfDebt | 1.00M | 0.00 | ||
| IssuanceOfCapitalStock | 11.81M | 7.02M | 25.19M | 14.29M |
| InterestPaidSupplementalData | 143.00K | 0.00 | ||
| EndCashPosition | 2.66M | 3.85M | 13.25M | 9.36M |
| BeginningCashPosition | 3.85M | 13.25M | 9.36M | 14.06M |
| EffectOfExchangeRateChanges | -4.00K | 7.00K | 105.00K | -140.73K |
| ChangesInCash | -1.18M | -9.41M | 3.78M | -4.55M |
| FinancingCashFlow | 10.99M | 7.02M | 25.29M | 14.29M |
| CashFlowFromContinuingFinancingActivities | 10.99M | 7.02M | 25.29M | 14.29M |
| ProceedsFromStockOptionExercised | 28.00K | 4.00K | 94.00K | 0.00 |
| NetCommonStockIssuance | 11.81M | 7.02M | 25.19M | 14.29M |
| CommonStockIssuance | 11.81M | 7.02M | 25.19M | 14.29M |
| NetIssuancePaymentsOfDebt | -855.00K | 0.00 | ||
| NetShortTermDebtIssuance | -855.00K | 0.00 | ||
| ShortTermDebtPayments | -1.85M | 0.00 | ||
| ShortTermDebtIssuance | 1.00M | 0.00 | ||
| InvestingCashFlow | 382.00K | 0.00 | ||
| CashFlowFromContinuingInvestingActivities | 382.00K | 0.00 | ||
| NetBusinessPurchaseAndSale | 382.00K | 0.00 | ||
| SaleOfBusiness | 382.00K | 0.00 | ||
| OperatingCashFlow | -12.55M | -16.43M | -21.50M | -18.85M |
| CashFlowFromContinuingOperatingActivities | -12.55M | -16.43M | -21.50M | -18.85M |
| ChangeInWorkingCapital | 6.54M | -866.00K | 822.00K | -1.98M |
| ChangeInPayablesAndAccruedExpense | 5.22M | -936.00K | -877.00K | -241.31K |
| ChangeInPrepaidAssets | 1.32M | 70.00K | 1.70M | -1.74M |
| OtherNonCashItems | 271.00K | 142.00K | ||
| StockBasedCompensation | 2.25M | 1.15M | 735.00K | 314.65K |
| DepreciationAmortizationDepletion | 14.00K | 4.00K | 4.00K | 4.13K |
| DepreciationAndAmortization | 14.00K | 4.00K | 4.00K | 4.13K |
| OperatingGainsLosses | -1.83M | -6.85M | -5.32M | 242.50K |
| GainLossOnInvestmentSecurities | -2.08M | -6.60M | -4.98M | |
| NetForeignCurrencyExchangeGainLoss | 255.00K | -255.00K | -334.00K | 242.50K |
| NetIncomeFromContinuingOperations | -19.79M | -10.01M | -17.75M | -17.42M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for AKTX
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|